Gland Pharma (NSE:GLAND) Marketable Securities: ₹737 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAND Gland Pharma Ltd NSE:GLAND
84 GF Score
Price ₹2,465.10
GF Value ₹2,140.91
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Marketable Securities?

Gland Pharma NSE:GLAND -0.93% 84 Marketable Securities is ₹737 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,140.91 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Gland Pharma's Marketable Securities for the quarter that ended in Mar. 2026 was ₹737 Mil.

Gland Pharma's annual Marketable Securities declined from Mar. 2024 (₹15,817 Mil) to Mar. 2025 (₹3,960 Mil) and declined from Mar. 2025 (₹3,960 Mil) to Mar. 2026 (₹737 Mil).

Gland Pharma  (NSE:GLAND) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Gland Pharma Marketable Securities Related Terms

Gland Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Marketable Securities Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 29,268.93 18,539.35 15,816.62 3,960.00 737.41

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,960.00 0.00 4,979.40 0.00 737.41
NSE:GLAND
84GF Score
Gland Pharma Ltd NSE:GLAND
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹737 Mil mean?
Gland Pharma (NSE:GLAND) has a Marketable Securities of ₹737 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Marketable Securities too high?
Gland Pharma's current Marketable Securities is ₹737 Mil. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Marketable Securities compare to ZTS and UTHR?
Gland Pharma's Marketable Securities of ₹737 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Gland Pharma and its competitors. Gland Pharma's current Marketable Securities is ₹737 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,140.91, compared to a current price of ₹2,465.10 — trading 15.1% above its estimated fair value. The current Marketable Securities is ₹737 Mil. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Marketable Securities is ₹737 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,465.10 is trading 15.1% above its estimated GF Value™ of ₹2,140.91. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Marketable Securities: ₹737 Mil
  • GF Value™: ₹2,140.91 vs. price of ₹2,465.10 (15.1% above fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score

Get the complete analysis for NSE:GLAND

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,465.10
Price
₹2,140.91
GF Value